Transcriptomic profiling of peripheral blood mononuclear cells from rheumatoid arthritis patients before tofacitinib treatment

This study explores the molecular mechanisms underlying variable therapeutic responses to tofacitinib in patients with rheumatoid arthritis (RA). Peripheral blood mononuclear cells (PBMCs) were collected from patients with active RA before tofacitinib treatment. Based on EULAR DAS28-defined clinical outcomes after 8 weeks of therapy, patients were classified as responders or non-responders. RNA sequencing (RNA-seq) was performed to characterize transcriptomic changes associated with treatment response. The resulting dataset provides valuable insights into immune-related transcriptional alterations linked to JAK inhibitor efficacy in RA and offers a useful resource for biomarker discovery and precision medicine research.

本研究旨在探究类风湿关节炎（RA）患者对托法替布治疗应答存在异质性的分子机制。研究于托法替布治疗前，从活动性类风湿关节炎患者体内采集外周血单个核细胞（PBMCs），并基于治疗8周后欧洲抗风湿病联盟（EULAR）依据DAS28制定的临床结局，将患者分为应答者与无应答者。随后通过RNA测序（RNA-seq）技术，对与治疗应答相关的转录组变化进行表征分析。本数据集可为类风湿关节炎中与JAK抑制剂（JAK inhibitor）疗效相关的免疫相关转录组改变提供重要见解，并为生物标志物发现及精准医学研究提供宝贵的研究资源。